- Dr. Gordon Freeman says many new cancer therapies being tested by drug companies exist thanks to federally backed basic science conducted at U.S. universities.
- Checkpoint inhibitors seem to be providing uniquely long-term benefits for cancer patients. “The field is just afire now,” says immunologist Dr. Gordon Freeman.
- Two-time cancer survivor and Pan-Mass Challenge rider Dan Haley talks about his experiences as a Dana-Farber patient and PMC fundraiser.
Tags: JimmyFund, PanMassChallenge
- Kathy Giusti, a Dana-Farber patient and founder of the Multiple Myeloma Research Foundation, and Dr. John Quakenbush comment on Boston's prominence in the world of biotech research.
- Dr. Mark Kieran, clinical director of the Brain Tumor Center, said atypical teratoid rhabdoid tumor, or AT/RT, is so rare that Dana-Farber sees fewer than half a dozen patients a year.
Tags: ChildhoodCancer, BrainTumors
- Dr. Paul Richardson, clinical director for Dana-Farber's Jerome Lipper Center for Multiple Myeloma, shared the latest prognosis on treating and surviving this disease.
- Dr. Ann Partridge comments on a new study that shows women ages 40 to 59, who had yearly mammograms, received no added survival benefit up to 25 years later compared with those who skipped the screening.
- Stacy Kennedy, a senior nutritionist at Dana-Farber, gave a presentation called “Fighting Cancer with Your Fork,” a culinary guide to wellness and cancer prevention.
Tags: Nutrition, PatientSupport
- Dana-Farber researchers, including Dr. Kornelia Polyak, have developed a mathematical model to predict how a patient’s tumor is likely to behave and which of several possible treatments is most likely to be effective.
Tags: BreastCancer, Genomics
- According to Dr. Stephen E. Sallan, the way we bring new pediatric drugs to market does not always serve the best interests of children with life-threatening illness for whom few options exist
Showing 11-20 of 360 items